Is MSI Testing Using NGS Data Accurate?
US FDA approves treatment for cancers with high microsatellite instability (MSI-H) highlight the importance of MSI testing in cancer treatment ; more and more companies adopting to use NGS data for MSI assessment, and the biggest benefit of NGS-based MS
Ovarian Cancer Patient: Ms. Chang
While fighting ovarian cancer for 18 years, Ms. Chang underwent several rounds of chemotherapy and surgery. At her last check-up, her cancer was found to have metastasized. She was at the point of accepting her fate when her attending doctor recommended genomic profiling, which led to a treatment recommendation that had not previously been considered.
Squamous Cell Skin Cancer Patient: Ms. Chen
The family members of 87-year-old Ms. Chen were reluctant that she be made to endure another surgery when her cancer relapsed owing to her age and effects of previous surgeries. Genomic profiling was then explored with her doctor to identify if she might be a candidate of immunotherapy. Fortunately, she is.
Stage 4 Lung Cancer Survivor: Mr. Yu
Mr. Yu wasn't a good candidate for targeted therapies owing to his negative results from the usual lung cancer biomarkers testing. His doctor later recommended a broader genomic panel, which provides a more comprehensive coverage, and eventually identified an important mutation that led to an effective treatment.